KATP Channel Loss for Type 2 Diabetes
(BC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those who have changed their diabetes medication in the past 3 months or use medications that could affect the study's outcomes. It's best to discuss your specific medications with the research team.
Is the KATP channel treatment generally safe for humans?
Research on diazoxide, a drug that affects KATP channels, shows it can increase insulin secretion without harmful effects on beta cell function, suggesting it may be safe for long-term use. However, diazoxide can also cause arrhythmias (irregular heartbeats) in people with type 2 diabetes, indicating potential safety concerns.12345
How does the KATP channel loss treatment for type 2 diabetes differ from other treatments?
The KATP channel loss treatment is unique because it targets the ATP-sensitive potassium channels in pancreatic beta cells, which are crucial for insulin secretion. Unlike other treatments that may focus on increasing insulin sensitivity or directly stimulating insulin release, this approach addresses the impaired glucose response by modifying the function of these specific channels, potentially offering a novel way to manage insulin secretion in type 2 diabetes.36789
What data supports the effectiveness of the drug Glipizide for Type 2 Diabetes?
Are You a Good Fit for This Trial?
This trial is for adults with type 2 diabetes, who may also have high blood pressure and obesity. Participants should not be on any medication that affects KATP channels or insulin secretion. Pregnant women and individuals with other significant health issues are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of the KATP antagonist glipizide (5mg) to assess insulin secretion
Follow-up
Participants are monitored for insulin secretion and KATP channel activity after glipizide ingestion
What Are the Treatments Tested in This Trial?
Interventions
- Glipizide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator